Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semaglutide implant - Vivani Medical

Next Previous
Drug Profile

Semaglutide implant - Vivani Medical

Alternative Names: NPM-133; NPM-139; Semaglutide NanoPortal implant - Vivani Medical

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nano Precision Medical
  • Developer Vivani Medical
  • Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 07 Jul 2026 Vivani Medical enters into a evaluation agreement with Novo Nordisk to evaluate the semaglutide implant implant for Obesity
  • 25 Jun 2026 Vivani Medical receives approval from Bellberry human research ethics committee to initiate a phase I SLIM-1™ trial for Obesity in Australia
  • 14 May 2026 Vivani Medical plans a phase II SLIM-2 dose ranging trial for Obesity (implant) in 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top